Orion (OEC)

NYSE Mercado cerrado

Orion S.A. is a global producer of carbon black, a finely divided form of carbon used to change the strength, durability, conductivity, colour, and processing characteristics of industrial materials. The company supplies customers across automotive, tire, coatings, plastics, printing, battery, and other specialty markets, making it part of the chemical supply chain behind many everyday and industrial products.

Orion reports its business through two main segments: Rubber Carbon Black and Specialty Carbon Black. Rubber Carbon Black is the larger revenue contributor and is primarily used to reinforce tires and mechanical rubber goods, where it helps improve wear resistance, tensile strength, and overall performance. Demand in this segment is closely tied to tire production, vehicle use, replacement tire cycles, and broader industrial activity.

The Specialty Carbon Black segment serves higher-value applications where carbon black functions as a pigment or performance additive. These products are used in coatings, inks, polymers, cables, conductive compounds, and other applications that require specific colour, electrical, or technical properties. Specialty grades can be more customized than standard rubber grades, giving Orion exposure to markets where material performance is a key purchasing factor.

The company operates internationally, with a significant revenue base in Europe and particularly Germany, according to its reported geographic mix. Orion’s position is shaped by manufacturing scale, technical know-how, customer qualification requirements, and the need to meet environmental and quality standards in a heavily regulated chemicals industry.

6.72 USD
6.00 USD
−0.46 (-6.41%)
Fuera de horario

Última actualización

Capitalización
404.87M
PER
Precio/FCF
11.53
Precio/Ventas
0.23
Valor de empresa
1.37B
Sector de actividad
Industria
Dirección
1700 CITY PLAZA DRIVE, SUITE 300, SPRING, TX, 77389
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2026

23 abr 2026, 11:00 A. M.
GlobeNewswire Inc.

Gabelli Hosts 17th Annual Specialty Chemicals Symposium

24 feb 2026, 14:00 P. M.
GlobeNewswire Inc.

Orion Group Interim Report January–September 2025

28 oct 2025, 11:00 A. M.
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–syyskuu 2025

28 oct 2025, 11:00 A. M.
GlobeNewswire Inc.

Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2025

18 jul 2025, 11:00 A. M.
GlobeNewswire Inc.

Sisäpiiritieto: Orion parantaa näkymäarviota vuodelle 2025

09 jul 2025, 12:00 P. M.
GlobeNewswire Inc.

Orion ja Glykos laajentavat tutkimusyhteistyö- ja lisenssisopimustaan seuraavan sukupolven vasta-ainekonjugaattien kehittämiseksi

17 jun 2025, 08:00 A. M.
GlobeNewswire Inc.

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

17 jun 2025, 08:00 A. M.
GlobeNewswire Inc.

Orionin yhteistyökumppani MSD laajentaa opevesostaatin kliinistä kehitysohjelmaa naisten syöpiin

21 may 2025, 06:30 A. M.
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2025

23 abr 2025, 11:00 A. M.
GlobeNewswire Inc.

Lääketeollisuus luovutti hallitukselle arvolupauksen: miljarditason investoinnit vuoteen 2030 mennessä

21 mar 2025, 12:00 P. M.
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

07 ene 2025, 08:00 A. M.
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee Kiinassa kolmatta indikaatiota darolutamidille

07 ene 2025, 08:00 A. M.
GlobeNewswire Inc.

Orion ja Abilita Therapeutics sopivat tutkimusyhteistyöstä ja lisenssisopimusoptiosta innovatiivisten vasta-ainehoitojen kehittämiseksi

18 dic 2024, 16:00 P. M.
GlobeNewswire Inc.

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

18 dic 2024, 16:00 P. M.
GlobeNewswire Inc.

Sisäpiiritieto: Orion lopettaa ODM-111-kehitysohjelman perustuen molekyylin liian kapeaan terapeuttiseen ikkunaan

24 oct 2024, 18:50 P. M.
GlobeNewswire Inc.

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

24 oct 2024, 18:50 P. M.
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee EU:ssa kolmatta indikaatiota darolutamidille

14 oct 2024, 10:00 A. M.
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

14 oct 2024, 10:00 A. M.
GlobeNewswire Inc.

Darolutamidi yhdessä ADT-hoidon kanssa pienensi merkitsevästi (46 prosentilla) syövän etenemisen tai kuoleman riskiä verrattuna lumelääkkeen ja ADT:n yhdistelmään levinnyttä hormonisensitiivistä eturauhassyöpää sairastavilla potilailla

16 sept 2024, 10:30 A. M.
Capitalización
404.87M
Valor de empresa
1.37B
PER
Precio/Valor contable
1.07
Precio/Ventas
0.23
VE / EBITDA
6.46
VE / Ventas
0.76
BPA
-1.58
Rendimiento por dividendo
1.16%
Precio/FCF
11.53
Precio/Flujo de caja
1.99
Flujo de caja libre
35.1M
Rent. sobre fondos propios
-23.48%
Rent. sobre activos
-4.61%
Deuda / Patrimonio
2.67
Ratio corriente
1
Prueba ácida
0.62
Efectivo
0.08
Vol. medio
460.53K
Precio de referencia fundamental
7.18

Cuenta de resultados

Partida 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Ingresos 459.5M 411.7M 450.9M 466.4M 477.7M
Beneficio bruto 79.2M 77.7M 85.6M 98.4M 98.1M
Resultado operativo 11.4M 13.5M -52.3M 32.1M 31.2M
EBITDA operativo 44.1M 41.3M 62.2M 64.1M 62.7M
Beneficio neto -9.9M -21.1M -67.1M 9M 9.1M
BPA básico -0.18 -0.37 -1.2 0.16 0.16
BPA diluido -0.18 -0.37 -1.2 0.16 0.16

Balance

Partida 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Activos totales 1.93B 1.91B 1.96B 2.02B 1.97B
Pasivos totales 1.55B 1.52B 1.56B 1.56B 1.5B
Patrimonio neto 379.5M 384.6M 401.8M 466.5M 466.1M
Efectivo y equivalentes 50.5M 60.7M 51.3M 42.6M 37.5M
Activos corrientes 661.5M 643.8M 683.5M 682.5M 688.6M
Pasivos corrientes 659.7M 626.4M 635.3M 620.8M 601.9M

Flujo de caja

Partida 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Flujo de caja operativo -12.4M 92.9M 68.8M 53.7M 400K
Flujo de caja de inversión -36.1M -48.7M -40.9M -42.2M -29.2M
Flujo de caja de financiación 39.6M -35.7M -19.5M -7.8M 21.8M
Variación de efectivo -8.9M 8.5M 8.4M 3.7M -7M
Tipo Informe Fecha Enlace
edgar index 8-K — Orion S.A. Ver informe
edgar index 10-Q — Orion S.A. Ver informe
eight k text 8-K — 8-K Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
form 4 Form 4 — Niewiem Sandra Ver informe
form 4 Form 4 — Painter Corning F. Ver informe
form 4 Form 4 — Puckett Jonathan A. Ver informe
form 4 Form 4 — Quinones Carlos Ver informe
form 4 Form 4 — Riveros Pedro Ver informe
edgar index ARS — Orion S.A. Ver informe
edgar index DEF 14A — Orion S.A. Ver informe
edgar index 8-K — Orion S.A. Ver informe
eight k text 8-K — 8-K Ver informe
edgar index PRE 14A — Orion S.A. Ver informe
edgar index 8-K — Orion S.A. Ver informe
eight k text 8-K — 8-K Ver informe
edgar index 8-K — Orion S.A. Ver informe
eight k text 8-K — 8-K Ver informe
edgar index 8-K — Orion S.A. Ver informe
edgar index SCHEDULE 13G — Orion S.A. Ver informe
eight k text 8-K — 8-K Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
form 4 Form 4 — Niewiem Sandra Ver informe
form 4 Form 4 — Niewiem Sandra Ver informe
form 4 Form 4 — Niewiem Sandra Ver informe
form 4 Form 4 — Painter Corning F. Ver informe
form 4 Form 4 — Painter Corning F. Ver informe
form 4 Form 4 — Painter Corning F. Ver informe
form 4 Form 4 — Quinones Carlos Ver informe
form 4 Form 4 — Quinones Carlos Ver informe
form 4 Form 4 — Quinones Carlos Ver informe
form 4 Form 4 — Riveros Pedro Ver informe
form 4 Form 4 — Riveros Pedro Ver informe
form 4 Form 4 — Riveros Pedro Ver informe
edgar index 8-K — Orion S.A. Ver informe
edgar index 10-K — Orion S.A. Ver informe
eight k text 8-K — 8-K Ver informe
ten k section 10-K — business Ver informe
ten k section 10-K — mda Ver informe
ten k section 10-K — risk_factors Ver informe
edgar index 4 — Orion S.A. Ver informe
form 4 Form 4 — Puckett Jonathan A. Ver informe
edgar index 3 — Orion S.A. Ver informe
edgar index 8-K — Orion S.A. Ver informe
eight k text 8-K — 8-K Ver informe
edgar index 8-K — Orion S.A. Ver informe
edgar index 10-Q — Orion S.A. Ver informe
eight k text 8-K — 8-K Ver informe
edgar index 8-K — Orion S.A. Ver informe
eight k text 8-K — 8-K Ver informe
edgar index 8-K — Orion S.A. Ver informe
eight k text 8-K — 8-K Ver informe
edgar index 8-K — Orion S.A. Ver informe
edgar index 8-K — Orion S.A. Ver informe
edgar index 10-Q — Orion S.A. Ver informe
edgar index SCHEDULE 13G/A — Orion S.A. Ver informe
edgar index 8-K — Orion S.A. Ver informe
edgar index SCHEDULE 13G/A — Orion S.A. Ver informe
edgar index 3 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
edgar index 4 — Orion S.A. Ver informe
form 4 Form 4 — GALVIN KERRY A Ver informe